

Christopher Wai Kei Lam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9093336/publications.pdf>

Version: 2024-02-01

43
papers

1,290
citations

361413

20
h-index

361022

35
g-index

43
all docs

43
docs citations

43
times ranked

2275
citing authors

#	ARTICLE	IF	CITATIONS
1	Ganoderma lucidum (Lingzhi™), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. <i>British Journal of Nutrition</i> , 2004, 91, 263-269.	2.3	121
2	Anti-Inflammatory Activities of Pentaherbs Formula, Berberine, Gallic Acid and Chlorogenic Acid in Atopic Dermatitis-Like Skin Inflammation. <i>Molecules</i> , 2016, 21, 519.	3.8	104
3	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM α) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	6.8	104
4	Effects of polymorphisms in <i>ABCG2</i> , <i>SLCO1B1</i> , <i>SLC10A1</i> and <i>CYP2C9</i> on plasma concentrations of rosuvastatin and lipid response in Chinese patients. <i>Pharmacogenomics</i> , 2013, 14, 1283-1294.	1.3	94
5	Natural Products from Chinese Medicines with Potential Benefits to Bone Health. <i>Molecules</i> , 2016, 21, 239.	3.8	81
6	Consumption of Sugar-Sweetened Beverages Has a Dose-Dependent Effect on the Risk of Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Dose-Response Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2192.	2.6	67
7	Preparation and Optimization of Triptolide-Loaded Solid Lipid Nanoparticles for Oral Delivery with Reduced Gastric Irritation. <i>Molecules</i> , 2013, 18, 13340-13356.	3.8	54
8	Ganoderma lucidum (Lingzhi™); acute and short-term biomarker response to supplementation. <i>International Journal of Food Sciences and Nutrition</i> , 2004, 55, 75-83.	2.8	52
9	Elevated Expression and Pro-Inflammatory Activity of IL-36 in Patients with Systemic Lupus Erythematosus. <i>Molecules</i> , 2015, 20, 19588-19604.	3.8	50
10	New Potential Pharmacological Functions of Chinese Herbal Medicines via Regulation of Autophagy. <i>Molecules</i> , 2016, 21, 359.	3.8	50
11	Study of potential cardioprotective effects of <i>Ganoderma lucidum</i> (Lingzhi): results of a controlled human intervention trial. <i>British Journal of Nutrition</i> , 2012, 107, 1017-1027.	2.3	49
12	Aberrant Expression of Novel Cytokine IL-38 and Regulatory T Lymphocytes in Childhood Asthma. <i>Molecules</i> , 2016, 21, 933.	3.8	49
13	An overview of new GLP-1 receptor agonists for type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 145-158.	4.1	41
14	Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 51-65.	3.3	33
15	Anti-Inflammatory Activities of Pentaherbs formula and Its Influence on Gut Microbiota in Allergic Asthma. <i>Molecules</i> , 2018, 23, 2776.	3.8	31
16	Statin Responses in Chinese Patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 199-202.	2.0	24
17	Alirocumab for the treatment of hypercholesterolemia. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 633-643.	3.1	23
18	A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 93, 456-467.	4.0	22

#	ARTICLE	IF	CITATIONS
19	Clinical Signs, Staphylococcus and Atopic Eczema-Related Seromarkers. <i>Molecules</i> , 2017, 22, 291.	3.8	21
20	Pharmacogenomics of lipid-lowering therapies. <i>Pharmacogenomics</i> , 2013, 14, 981-995.	1.3	20
21	Precision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal Medicine. <i>Molecules</i> , 2016, 21, 889.	3.8	20
22	Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 211-223.	3.3	16
23	The beneficial effects of <i>Ganoderma lucidum</i> on cardiovascular and metabolic disease risk. <i>Pharmaceutical Biology</i> , 2021, 59, 1159-1169.	2.9	16
24	Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia. <i>Endocrinology and Metabolism</i> , 2021, 36, 279-295.	3.0	16
25	Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2016, 32, 1097-1108.	1.9	14
26	Managing dyslipidemia in patients with Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2221-2234.	1.8	14
27	The role of sulfonylureas in the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 387-403.	1.8	14
28	Aberrant Expression of Bacterial Pattern Recognition Receptor NOD2 of Basophils and Microbicidal Peptides in Atopic Dermatitis. <i>Molecules</i> , 2016, 21, 471.	3.8	13
29	Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2020, 15, 147-157.	2.4	12
30	Pharmacokinetics of current and emerging treatments for hypercholesterolemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 371-385.	3.3	9
31	A case of simvastatin-induced myopathy with <i>SLCO1B1</i> genetic predisposition and co-ingestion of linagliptin and <i>Stevia rebaudiana</i> . <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 381-383.	1.5	9
32	Effects of Concomitant Therapy with Diltiazem on the Lipid Responses to Simvastatin in Chinese Subjects. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 1151-1158.	2.0	8
33	Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1267-1271.	3.3	8
34	Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2137-2151.	1.8	7
35	An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, , 1-9.	3.3	7
36	Effect of <i>Phyllanthus amarus</i> Extract on 5-Fluorouracil-Induced Perturbations in Ribonucleotide and Deoxyribonucleotide Pools in HepG2 Cell Line. <i>Molecules</i> , 2016, 21, 1254.	3.8	5

#	ARTICLE	IF	CITATIONS
37	Evolocumab for the treatment of hypercholesterolemia. Expert Opinion on Biological Therapy, 2017, 17, 1-15.	3.1	5
38	An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2022, 23, 29-42.	1.8	4
39	Personalized medicine in lipid-modifying therapy. Personalized Medicine, 2021, 18, 185-203.	1.5	2
40	Effects of Soy Isoflavones and Green Tea Extract on Simvastatin Pharmacokinetics and Influence of the SLCO1B1 521T & C Polymorphism. Frontiers in Nutrition, 2022, 9, .	3.7	1
41	Statin Controversies Continued: Response to the Letter from Azemawah et al.. Cardiovascular Drugs and Therapy, 2020, 34, 887-888.	2.6	0
42	Statin Pharmacology Revisited. Cardiovascular Drugs and Therapy, 2020, 34, 225-226.	2.6	0
43	Is There Still a Role for Sulfonylureas in Type 2 Diabetes?. Current Pharmacogenomics and Personalized Medicine, 2021, 18, .	0.2	0